Advances in PSMA-targeted radioligands for the treatment of mCRPC
10.3760/cma.j.cn112330-20240906-00399
- VernacularTitle:PSMA靶向放射性核素配体在mCRPC治疗中的研究进展
- Author:
Yu ZHAO
1
;
Chong MA
;
Jingfei TENG
;
Dongshan LIU
;
Xing AI
Author Information
1. 三峡大学基础医学院，宜昌 443000
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Metastatic castration-resistant prostate cancer;
Prostate-specific membrane antigen;
Radioligand therapy
- From:
Chinese Journal of Urology
2025;46(3):237-240
- CountryChina
- Language:Chinese
-
Abstract:
Metastatic castration-resistant prostate cancer (mCRPC) is often resistant to conventional therapies, and prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy has emerged as a promising therapeutic strategy. Ligands such as 177Lu-PSMA and 225Ac-PSMA have demonstrated clinical benefits in ongoing studies and show potential when combined with endocrine therapy, chemotherapy, immunotherapy, and radiotherapy. Additionally, novel therapeutic approaches, including PSMA-targeted antibody-drug conjugates (ADCs), chimeric antigen receptor T-cell (CAR-T) therapy, and bispecific T-cell engagers (BiTEs), are being actively explored. This review summarizes the recent advancements in PSMA-targeted treatment and their clinical applications.
